Department of Allergy, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
ARADyAL - RETICS Network RD16, Instituto de Salud Carlos III, IIS-P, FibHNJ, Madrid, Spain;
Allergol Immunopathol (Madr). 2022 Jan 1;50(1):99-103. doi: 10.15586/aei.v50i1.492. eCollection 2022.
The novel disease caused by the new coronavirus SARS-CoV-2 has caused an unprecedented global pandemic. Care providers of asthmatic children are increasingly con-cerned; as viral infections are one of the primary triggers of asthma flare-up. However, the effect of SARS-CoV-2 as well as the generated worldwide lockdown on asthmatic children is unknown.
The aim of this study was to analyze the effects of pandemic SARS-CoV-2 in pediat-ric asthma control.
A retrospective, open, transversal study was performed at five ter-tiary hospitals. Recruited patients were aged <18 years and had physician-diagnosed asthma. Information regarding the 2019 and 2020 seasons were provided.
Data were collected from 107 children (age range: 3-18 years, mean age: 12 years). Well-controlled asthma was observed in 58 (54.2%) patients in 2020 versus 30 (28%) in 2019, and 15 (14%) patients had poorly controlled asthma in 2020 versus 28 (26.2%) in 2019. In 2020, a decrease in exacerbations caused by allergies to pollen, dust mites, molds, and through other causes not related to SARS-CoV-2 infection was observed. An increase in exacerbations was observed due to animal dander, stress, physical exercise, and SARSCoV-2 infection. Children had a reduced need for asthma-controlling medication, made fewer visits to healthcare providers and had lesser need of treatment with oral corticosteroids if compared with the same season of 2019.
Pediatric asthma control improved, the need for controller medication declined, and fewer visits to healthcare providers were made during the pandemic if compared with the 2019 season.
由新型冠状病毒 SARS-CoV-2 引起的新型疾病导致了前所未有的全球大流行。哮喘儿童的护理人员越来越关注；因为病毒感染是哮喘发作的主要诱因之一。然而，SARS-CoV-2 以及全球范围内的封锁对哮喘儿童的影响尚不清楚。
本研究旨在分析大流行 SARS-CoV-2 对儿科哮喘控制的影响。
在五家三级医院进行了回顾性、开放性、横断面研究。招募的患者年龄<18 岁，且经医生诊断患有哮喘。提供了 2019 年和 2020 年两个季节的信息。
共收集了 107 名儿童（年龄 3-18 岁，平均年龄 12 岁）的数据。2020 年，58 名（54.2%）患者哮喘得到良好控制，而 2019 年为 30 名（28%）；2020 年 15 名（14%）患者哮喘控制不佳，而 2019 年为 28 名（26.2%）。2020 年，由于花粉、尘螨、霉菌过敏以及与 SARS-CoV-2 感染无关的其他原因导致的哮喘发作减少。由于动物皮屑、压力、体育锻炼和 SARS-CoV-2 感染，哮喘发作增加。与 2019 年同期相比，儿童对哮喘控制药物的需求减少，就诊次数减少，需要口服皮质类固醇治疗的情况也减少。
与 2019 年同期相比，大流行期间儿科哮喘控制有所改善，对控制药物的需求减少，就诊次数减少。
